MARKET WIRESeekingAlpha • 4d ago
Riverwater Small Cap Strategy Q3 2026 Portfolio UpdateTop contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. Read more here.
Why PBH Stock surged +2.01% Today — RQD Quant Desk Flash
$48.75 +2.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $49.04
Prestige Consumer Healthcare Inc. (PBH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (55% profit margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $2.31B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $49.04 (+0.60%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 22.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBH)Realized 20D OHLCV Swing Band: ±6.2%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY PBH SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+18/20 pts (25% of score)
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 54.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)
Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$48.23+3.5% Next Q
64
Q2 (-2Q)Grade B-$49.92-4.2% Next Q
67
Q3 (-1Q)Grade B-$47.80+2% Next Q
69
CurrentGrade B$48.75+7% Hist 90D α
72
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PBH Bull Thesis Could Fail
Even with a 72/100 (B) score, PBH faces multiple-compression risk if 12.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 52.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($48.53) or 200D SMA ($54.09) invalidates the momentum regime and cuts Target Base ($51.82) toward Bear Floor ($39.97).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBH Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PBH Stock surged +2.01% Today — RQD Quant Desk Flash
Prestige Consumer Healthcare Inc. (PBH) surged +2.01% to $48.75, trading at 22% of its 52-week range ($42.62 – $71.07). High-quality cash engine (55% profit margin, 14% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 22% of its 52-week range ($42.62 – $71.07) with RSI-14 at 54.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.2% around $48.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 54.7% gross margin and $246.4M annual free cash flow.
Live PBH Headlines & Catalysts
CATALYSTYahoo • 4d ago
GE HealthCare Technologies (GEHC) Q3 Earnings and Revenues Beat EstimatesGE HealthCare (GEHC) delivered earnings and revenue surprises of +10.74% and +2.87%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PBH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.44%⚡ TESTING RESISTANCE
2026-10-30O $50.23H $50.23L $48.75C $48.75VOL 371.5K
RES: $49.68SUP: $44.62SMA50: $48.53SMA200: $54.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PBH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
2.7%/yr Implied 5Y Growth
vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PBH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PBH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBH)
Health Care Rank #75 of 1016
⚔️ AUPH vs PBH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PBH vs. AUPH, PHVS, RCUS, HCM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Prestige Consumer Healthcare Inc. (PBH) ranks #75 by composite RQD confidence (72/100, grade B) and #236 by equity capitalization ($2.31B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PBH at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PBH
ACTIVE
Prestige Consumer Healthcare Inc. | B | 72/100 | 12.1x | 54.7% | 13.8% | +2.01% | $2.31B | Benchmark Subject |
| AUPH Aurinia Pharmaceuticals Inc | B | 75/100 | 8.0x | 88.5% | 16.5% | -0.86% | $2.29B | /auph-vs-pbh → |
| PHVS Pharvaris N.V. | C | 63/100 | — | — | — | +2.32% | $2.34B | /phvs-vs-pbh → |
| RCUS Arcus Biosciences Inc. | D- | 35/100 | — | — | -35.0% | +1.20% | $2.37B | /rcus-vs-pbh → |
| HCM HUTCHMED (China) Limited | D | 46/100 | 5.2x | — | -2.5% | +2.03% | $2.37B | /hcm-vs-pbh → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001295947In its most recent audited fiscal period (FY2025, filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported GAAP revenue of $1.09B (-4.3% vs. FY2024 revenue of $1.14B , and -3.3% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $257.6M, and free cash flow of $246.4M (+1.3% YoY). On the balance sheet, PBH closed FY2025 with $3.49B in total assets against $0 in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $1.09B | $190.3M | $257.6M | $246.4M | $3.49B | — |
| FY2024 (FY) | 2025-03-31 | $1.14B | $214.6M | $251.5M | $243.3M | $3.33B | $1.00B |
| FY2023 (FY) | 2024-03-31 | $1.13B | $209.3M | $248.9M | $248.9M | — | — |
3. PBH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $48.75 (+2.01% 1D, market cap $2.31B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBH ranks #75 in composite RQD confidence.
How does PBH compare to AUPH and PHVS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable B (72/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (75/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.29B) and PHVS (Pharvaris N.V.) posts a C grade (63/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while AUPH leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PBH?
Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PBH trading relative to its 50-day, 200-day, and 52-week technical levels?
PBH last traded at $48.75 (+2.01% on volume of 343,426 shares), positioning the stock +0.45% above its 50-day simple moving average ($48.53) and -9.87% below its 200-day simple moving average ($54.09). Across its 52-week range of $42.62 to $71.07, PBH sits at the 21.5% percentile with a 14-day RSI of 54.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($45.73 to $51.77).
PBH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PBH stock moving today?
Why PBH Stock surged +2.01% Today — RQD Quant Desk Flash. High-quality cash engine (55% profit margin, 14% return on capital) with steady institutional support.